IndraLab
Statements
reach
"Among the compounds targeting USP9X, a non specific inhibitor of USP9X, named (EOAI3402143) G9, belonging to the USP9X-second generation inhibitors, has been shown to destabilize the pro survival protein MCL1 and increased p53 levels, promoting apoptosis in a dose dependent manner and reducing tumor growth of human myeloma xenograft [XREF_BIBR]."